



Image

2-19-04

1647

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/996357-Conf. #1918	
	Filing Date	November 27, 2001	
	First Named Inventor	Malcolm L. Geffer	
	Art Unit	1647	
	Examiner Name	NICHOLS, CHRISTOPHER J	
Total Number of Pages in This Submission	1	Attorney Docket Number	PPI-105

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Response to Restriction Requirement (2 pages); and
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	A Pre-Paid Return Acknowledgment Postcard.
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	LAHIVE & COCKFIELD, LLP Jane E. Remillard - 38,872
Signature	
Date	February 17, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 309882266 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: February 17, 2004	Signature:  (Jane E. Remillard)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 309882266 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 17, 2004

Signature:

(Jane E. Remillard)

Docket No.: PPI-105  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Malcolm L. Geffer

Application No.: 09/996357

Confirmation No.: 1918

Filed: November 27, 2001

Art Unit: 1647

For: THERAPEUTIC AGENTS AND METHODS  
OF USE THEREOF FOR TREATING  
AMYLOIDOGENIC DISEASE

Examiner:  
NICHOLS, CHRISTOPHER J

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the restriction requirement set forth in the Office Action mailed January 14, 2004.

The Examiner has required restriction among the following inventions in the above-identified application:

- I. Claims 1-22, drawn to a compound comprising the formula I-L-P and pharmaceutical compositions thereof, classified in class 424, subclass 130.1, for example;
- II. Claims 23-26, drawn to a method for treating a subject suffering from an amyloidogenic disorder, classification dependent upon compound structure used.
- III. Claims 27-52, drawn to a method of producing a polypeptide, nucleic acids, vectors, and recombinant cells comprising same, classified in class 435, subclass 325;
- IV. Claims 53-73, drawn to a polypeptide comprising an immunoglobulin heavy chain constant region, or fragment thereof, that retains the ability to bind an Fc receptor



Application No.: 09/996357

Docket No.: PPI-105

and an amino acid sequence capable of binding to an amyloidogenic protein,  
classified in class 530, subclass 387.1;

- V. Claims 74-76, drawn to a method of preparing a therapeutic agent, classification dependent upon agent structure;
- VI. Claims 77-78, drawn to a therapeutic agent, classification dependent upon agent structure.

Accordingly, Applicant(s) hereby elect(s) Group V (claims 74-76), drawn to a method of preparing a therapeutic agent.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. PPI-105 from which the undersigned is authorized to draw.

Dated: February 17, 2004

Respectfully submitted,

By

Jane E. Remillard

Registration No.: 38,872

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant